期刊文献+

中医治疗方案的“效果择优”及其应用朝向

Effectiveness Prioritization in Chinese Medicine Treatment and Application Orientation
下载PDF
导出
摘要 中医临床施治环节,针对具体病证,何药有效?存在多种治疗方案时,何药最优?是医生频繁抉择的临床问题。随着中药复方有效性证据知识的增加,"何药有效"正逐步被回答,而"何药最优"成为新近研究热点。基于上述认识,本研究提出效果择优的概念,进而阐明其对临床决策的价值,例举出现阶段可用于中医药效果择优研究的两类研究方法——间接比较法和多准则决策分析法,分析其方法学原理和具体应用环节。同时,针对多种慢病难治环节,提出中医药效果择优研究的基本流程及应用前景,为推动中医药高质量证据进入指南提供方法学实践策略。 During the clinical practice involving Chinese medicine, two questions repeatedly confronts the practition- ers are what prescription is effective and which prescription works better. As the trial and experimental evidences accumu- lating, the former has been better answered, while the latter, which is currently quite another story, increasingly fails into the interests of researchers. Based upon this situation, this paper proposed and tried to define the concept of effectiveness prioritization and clarified what sense it will make to Chinese medicine. Further, two practically available methods for such an end--indirect effectiveness comparison and multi -criteria decision -making process, were introduced with respect to their fundamental rationales and application prospects. Meanwhile, the authors also looked at the promise Of these methods in Chinese medicine and drafted its underlying workflow. All of these endeavors aim at better introducing high - quality evidence into clinical guideline.
出处 《中华中医药学刊》 CAS 北大核心 2016年第9期2113-2116,I0006,共5页 Chinese Archives of Traditional Chinese Medicine
基金 国家自然科学基金面上项目(81273876 81473800) 国家科技支撑计划课题(2013BAI02B10)
关键词 中医药 慢病防控 治疗方案 确切疗效 效果择优 TCM chronic disease prevention and control treatment prescription curative effect effectiveness priori-tization
  • 相关文献

参考文献17

  • 1李可建,马丽虹.生脉散制剂治疗2型糖尿病随机对照试验的系统评价[J].中成药,2009,31(1):20-23. 被引量:9
  • 2Last JM.A dictionary of Epidemiology[M].Oxford:Oxford University,1983.
  • 3Salanti G,Del Giovane C,Chaimani A,et al.Evaluating the Quality of Evidence from a Network Meta-Analysis[J].PLo S One,2014,9(7):e99682.
  • 4Krahn U,Binder H,Knig J.A graphical tool for locating inconsistency in network meta-analyses[J].BMC Med Res Methodol,2013,13(6):35.
  • 5Bucher HC,Guyatt GH,Griffith LE,et al.The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials[J].J Clin Epidemiol,1997,50(6):683-691.
  • 6Lumley T.Network meta-analysis for indirect treatment comparisons[J].Stat Med,2002,21(16):2313–2324.
  • 7Caldwell DM.An overview of conducting systematic reviews with network meta-analysis[J].Systematic Reviews,2014,3:109.
  • 8Cross JT,Garrison LP.Challenges and opportunities for improving benefit-risk assessment of pharmaceuticals from an economic perspective[M].London:Office of Health Economics,2008.
  • 9European Medicines Agency(EMA).Report of the CHMP working group on benefit-risk assessment models and methods[R].London:European Medicines Agency,2007.
  • 10European Medicines Agency(EMA).Benefit-risk methodology project.Work package 4 report:benefit-risk tools and processes[R].London:European Medicines Agency,2012.

二级参考文献6

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部